Institut Mutualiste Montsouris — Clinical Trial Site

78 Registered trials

37 Currently recruiting

Organisation

Institut Mutualiste Montsouris

Location

Paris, France

Identifier

ORG-100042997

Address

42 Boulevard Jourdan, 75014, France

Departments

1704:Urology
75674
Cancérologie
Cardiologie
Cardiology
Cardiology/EP
Chirurgie cardiaque
Département d'Oncologie Médicale
Département d’Oncologie Médicale
Département de Cardiologie et Rythmologie
Département Oncologie médicale
Digestive surgery
Gastroentérology
Intensive Care
Médecine Interne
Medical oncology
Medical oncology department
Medically assisted procreation
Mère-Enfant
N/A
Oncologie
Oncologie gastro-entérologie
Oncologie médicale
Oncologue
Oncology
Oncology clinic
Oncoloy
Pneumologie
Satellite site Pneumology Department
service d'oncologie
Service d'Urologie
Service d’Oncologie Médicale
Service de Médecine Interne
Service Oncologie
Surgery
Urologie
Urology

Clinical trials at this site (78)

Search interface

CANDISHORT : A randomized study of a short duration therapy for candidemia Pending

2024-514244-81-00 Uncomplicated candidemia 5
FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial Pending

2024-514964-24-00 ulcerative colitis 5
LEvOsimendaN vs. Placebo Before Tricuspid VAlve Surgery in Patients with Right Ventricular Dysfunction Pending

2024-516167-86-00 Patients referred for an isolated or a combined surgica 5
BICCS - Beta-lactam Intermittent versus Continuous infusion and Combination antibiotic therapy in Sepsis Pending

2024-516849-39-01 antibiotic therapy in Sepsis 5
Bosentan in the treatment of Giant Cell Arteritis Pending

2024-517030-17-00 Newly diagnosed or relapsing Giant-cell arteritis 4
A Phase III study evaluating the efficacy of atezoliumab administration in addition to BCG (Bacillus Calmette-Guerin) for 1 year in patient… Pending

2024-517621-54-00 High-risk non-muscle invasive bladder cancer (NMIBC) af 5
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) Pending

2024-518138-10-00 Patients with DMMR and/or MSI metastatic colorectal can 4
Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Duct… Pending

2024-518139-12-00 locally advanced or metastatic Pancreatic ductal adenoc 4
OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE Pending

2025-524573-16-00 Crohn's disease 6
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting

2024-513219-29-00 Renal Cell Carcinoma 5 2024-10-21
Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting

2023-504231-41-01 Locally advanced or metastatic urothelial cancer 10 2024-10-02
Efficacy of MIrikizumab to achieve traNsmural healing in patiENTs with Crohn’s Disease : EMINENT CD Recruiting

2025-521889-95-00 Crohn's Disease 6 2026-05-04
DIAMOND Study - DIrect oral anticoagulant for Antithrombotic Management Of aortic bioprothesis implanted patients for valvular heart Disease… Recruiting

2024-516643-64-00 Aortic bioprothesis implanted patient for valvular hear 5 2026-03-13
BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, … Recruiting

2024-520128-27-00 colorectal adenocarcinoma 4 2026-03-04
Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combin… Recruiting

2023-506291-28-00 Patient with locally advanced/metastatic, MSI-H/dMMR ga 5 2026-03-02
OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 pro… Recruiting

2022-501557-36-00 PR3-ANCA granulomatosis with polyangiitis (Wegener’s) 4 2025-12-19
Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with… Recruiting

2024-519048-33-00 resected pancreatic adenocarcinoma 10 2025-11-25
An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting

2024-520156-22-00 Metastatic hormone-sensitive prostate cancer 4 2025-10-08
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting

2024-515875-36-00 Advanced biliary tract cancer (BTC) 4 2025-08-18
A multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of BP1.4979 in adult p… Recruiting

2024-517996-19-00 Primary premature ejaculation 4 2025-06-19
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting

2023-506817-23-01 Metastatic hormone naïve prostate cancer (mHNPC) 5 2025-05-23
Clinical trial evaluating the efficacy of pemigatinib for the treatment of patients with solid tumours with an alteration of the gene FGFR Recruiting

2024-512729-10-00 Recurrent or metastatic solid cancer harboring a FGFR1, 4 2025-03-27